Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992564 | PMC |
| http://dx.doi.org/10.1093/europace/euaf063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fetal Supraventricular Tachycardia: What Do We Know up to This Day?
J Pers Med
August 2025
1st Department of Cardiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Fetal tachyarrhythmias, particularly supraventricular tachycardia (SVT) and atrial flutter (AFL), pose significant clinical challenges, especially when complicated by hydrops fetalis. This article provides a comprehensive review of the tachyarrhythmia types, the diagnostic modalities applied, and the therapeutic strategies followed in fetal tachyarrhythmias. Diagnostic techniques such as M-mode echocardiography and fetal magnetocardiography (fMCG) are highlighted for their capacity to provide real-time, high-quality assessments of fetal cardiac rhythms.
View Article and Find Full Text PDFFirst-line catheter ablation for atrial fibrillation - lower than recommended doses of antiarrhythmic drugs may have contributed to their inferiority: Analysis of randomized controlled studies comparing ablation with antiarrhythmic drugs.
Trends Cardiovasc Med
August 2025
Department of Cardiology II: Electrophysiology, University Hospital Muenster, Muenster, Germany; Atrial Fibrillation NETwork (AFNET), Menedelstr. 11, 48149 Muenster, Germany. Electronic address:
Catheter ablation plays a pivotal role in the management of atrial fibrillation (AF). Recent randomized controlled studies have shown that catheter ablation is superior to conventional antiarrhythmic medical treatment as first-line therapy in reducing symptoms, AF recurrences, and preventing progression of AF. If the examined antiarrhythmic medical regimens were given in therapeutic and adequate doses remains an open question.
View Article and Find Full Text PDFFlecainide fallout: a rare case report of refractory ventricular tachycardia and updated management strategies.
Eur Heart J Case Rep
August 2025
Department of Cardiology, All India Institute of Medical Sciences, Tatibandh, Raipur, Chhattisgarh 492009, India.
Background: Flecainide is a Class IC antiarrhythmic drug used to treat arrhythmias such as atrial fibrillation (AF), paroxysmal supraventricular tachycardia, and ventricular tachycardia (VT). Its mechanism involves blocking sodium channels, leading to QRS widening, especially at higher heart rates. This property increases the risk of pro-arrhythmic events, particularly in patients with structural heart disease or ischaemia.
View Article and Find Full Text PDFComprehensive Conduction System Pacing as Antiarrhythmic Strategy in Atrial Fibrillation.
JACC Case Rep
August 2025
Department of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.
Background: Elevated intracardiac filling pressures create a proarrhythmic environment that facilitates the development or progression of atrial fibrillation (AF). Accelerated lower rate pacing results in atrial decongestion by lowering intracardiac filling pressure and therefore may have an antiarrhythmic effect.
Case Summary: A 70-year-old woman with paroxysmal AF on flecainide progressed to symptomatic rate-controlled persistent AF 5 months ago.
Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study.
Int J Emerg Med
August 2025
Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro, Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana, Madrid, Spain.
Background: Vernakalant is authorized in several countries, except in the U.S., where the FDA denied its commercialization due to safety concerns, generating debate about its use.
View Article and Find Full Text PDF